The company provides global partners with a full range of new drug development and production services, covering all aspects of new drug research and development, so that anyone and any company can realize their dream of innovation through our enabling platform. We are committed to lowering the R&D threshold, improving R&D efficiency, promoting the early introduction of more new drugs and good drugs, and benefiting patients around the world through integrated and open capabilities and technology platforms. The company's main business can be divided into five major segments: chemical business (wuxiTesting), biology business (wuxiBiology), cell and gene therapy CTDMO business (wuxiTU), and domestic new drug development service department (wuxiDSU). The scope of services covers the entire process from concept generation to commercial production, and the service area includes China, the United States, Europe and other regions. Company honors include Baihua Association's “Enterprise of the Year Award”, Sina Pharmaceuticals's “Most Influential Enterprise in China's Pharmaceutical Industry”, and “China's 100 Model Employers” for four consecutive years.
No Data
No Data